Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,516 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies.
Stoch SA, Zajic S, Stone J, Miller DL, Van Dyck K, Gutierrez MJ, De Decker M, Liu L, Liu Q, Scott BB, Panebianco D, Jin B, Duong LT, Gottesdiener K, Wagner JA. Stoch SA, et al. Among authors: jin b. Clin Pharmacol Ther. 2009 Aug;86(2):175-82. doi: 10.1038/clpt.2009.60. Epub 2009 May 6. Clin Pharmacol Ther. 2009. PMID: 19421185 Clinical Trial.
Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.
Krishna R, Bergman AJ, Jin B, Fallon M, Cote J, Van Hoydonck P, Laethem T, Gendrano IN 3rd, Van Dyck K, Hilliard D, Laterza O, Snyder K, Chavez-Eng C, Lutz R, Chen J, Bloomfield DM, De Smet M, Van Bortel LM, Gutierrez M, Al-Huniti N, Dykstra K, Gottesdiener KM, Wagner JA. Krishna R, et al. Among authors: jin b. Clin Pharmacol Ther. 2008 Dec;84(6):679-83. doi: 10.1038/clpt.2008.109. Epub 2008 Jun 25. Clin Pharmacol Ther. 2008. PMID: 18580870 Clinical Trial. No abstract available.
Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms.
Wenning LA, Petry AS, Kost JT, Jin B, Breidinger SA, DeLepeleire I, Carlini EJ, Young S, Rushmore T, Wagner F, Lunde NM, Bieberdorf F, Greenberg H, Stone JA, Wagner JA, Iwamoto M. Wenning LA, et al. Among authors: jin b. Clin Pharmacol Ther. 2009 Jun;85(6):623-7. doi: 10.1038/clpt.2009.12. Epub 2009 Mar 11. Clin Pharmacol Ther. 2009. PMID: 19279563 Clinical Trial.
Assessment of the CYP3A-mediated drug interaction potential of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy volunteers.
Krishna R, Bergman AJ, Jin B, Garg A, Roadcap B, Chiou R, Dru J, Cote J, Laethem T, Wang RW, Didolkar V, Vets E, Gottesdiener K, Wagner JA. Krishna R, et al. Among authors: jin b. J Clin Pharmacol. 2009 Jan;49(1):80-7. doi: 10.1177/0091270008326718. Epub 2008 Nov 11. J Clin Pharmacol. 2009. PMID: 19004846 Clinical Trial.
Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.
Krishna R, Garg A, Jin B, Keshavarz SS, Bieberdorf FA, Chodakewitz J, Wagner JA. Krishna R, et al. Among authors: jin b. Br J Clin Pharmacol. 2009 May;67(5):520-6. doi: 10.1111/j.1365-2125.2009.03385.x. Epub 2009 Feb 4. Br J Clin Pharmacol. 2009. PMID: 19552746 Free PMC article. Clinical Trial.
Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.
Krishna R, Garg A, Panebianco D, Cote J, Bergman AJ, Van Hoydonck P, Laethem T, Van Dyck K, Chen J, Chavez-Eng C, Archer L, Lutz R, Hilliard D, Snyder K, Jin B, Van Bortel L, Lasseter KC, Al-Huniti N, Dykstra K, Gottesdiener K, Wagner JA. Krishna R, et al. Among authors: jin b. Br J Clin Pharmacol. 2009 Oct;68(4):535-45. doi: 10.1111/j.1365-2125.2009.03465.x. Br J Clin Pharmacol. 2009. PMID: 19843057 Free PMC article. Clinical Trial.
Effect of raltegravir on the pharmacokinetics of methadone.
Anderson MS, Mabalot Luk JA, Hanley WD, Jin B, Riesenberg RA, Wenning LA, Chodakewitz JA, Wagner JA, Iwamoto M. Anderson MS, et al. Among authors: jin b. J Clin Pharmacol. 2010 Dec;50(12):1461-6. doi: 10.1177/0091270009360981. Epub 2010 Feb 19. J Clin Pharmacol. 2010. PMID: 20173085 Clinical Trial.
Effect of diltiazem, a moderate CYP3A inhibitor, on the pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein inhibitor, in healthy subjects.
Garg A, Maes A, Corr C, Jin B, Wadhwa T, Handa N, Van Dyck K, De Lepeleire I, Shah J, Wagner JA, Krishna R. Garg A, et al. Among authors: jin b. J Clin Pharmacol. 2011 Mar;51(3):436-9. doi: 10.1177/0091270010368676. Epub 2010 Apr 23. J Clin Pharmacol. 2011. PMID: 20418508 Clinical Trial. No abstract available.
Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies.
Krishna R, Anderson MS, Bergman AJ, Jin B, Fallon M, Cote J, Rosko K, Chavez-Eng C, Lutz R, Bloomfield DM, Gutierrez M, Doherty J, Bieberdorf F, Chodakewitz J, Gottesdiener KM, Wagner JA. Krishna R, et al. Among authors: jin b. Lancet. 2007 Dec 8;370(9603):1907-14. doi: 10.1016/S0140-6736(07)61813-3. Lancet. 2007. PMID: 18068514 Clinical Trial.
3,516 results